ENGLISH ABSTRACT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Sub-urethral sling Advance(®) midterm results: patient selection and predictors of success].

INTRODUCTION AND OBJECTIVES: Sub-urethral trans-obturator male slings have been propose to treat men urinary incontinence. Medium term results are lacking: only one study has been published.

AIM: To evaluate the efficacy of the sub-urethral sling Advance(®) (American Medical System, Minnetonka, MN, USA) and determinate factor of success.

MATERIALS AND METHODS: Single center retrospective study of patients implanted with an Advance(®) for urinary incontinence after radical prostatectomy. The degree of incontinence was evaluated by number of pads used per days: mild (use of 1 to 2 pads/day), moderate (3 to 4p/day) and severe (≥5p/day). The "Cure" was defined as no pad or just one for "security reason" and "improved" as decreased more than 50% of pads use.

RESULTS: Between October 2007 and November 2009, 69 slings were implanted. Mean follow-up was 32.4months (±8.4months). Before treatment, 37.68% of the patients suffered from mild, 42.03% moderate and 20.29% severe urinary incontinence. At midterm, 21.8% of the patients were cured and 50.7% cured or improved. For patients who suffered from mild or moderate urinary incontinence, 23.6% were cured and 58.2% were cured or improved. The cure rate decreased with the severity of incontinence. It was respectively 30.8%, 17.2% and 14.2% for mild, moderate and severe incontinence. Failure rate was more important with severe incontinence: 78%. For patients with urethral fence pressure less than 57cmH2O, the risk of failure was multiply by 6.6. No severe complication was noted during follow-up. Only one male sling was removed.

CONCLUSIONS: At midterm, one patient on five was cure and half was cured or improved. The technique presented an acceptable morbidity and a good tolerance. Two predictors of success were identified: severity of incontinence and residual sphincter function. Good candidates used less than three pads per day.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app